Yu Kuang Lai, MD
Critical Care (Intensivists) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lai’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A141834 · Current
Licensed to practise in California · since 2016 · expires 2028-04-30 · Faculty of Health Sciences of the University of the Witwatersrand.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$81,559
Medicare paid this office $81,559 for 237 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 83 | $38,254 | $184 |
| Return visit (30+ min) | 34 | $6,319 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $5,937 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $4,639 | $70 |
| New patient visit (60+ min) | 22 | $3,585 | $163 |
See all 12 services
| Critical care, first 30-74 minutes | 83 | $38,254 | $184 |
| Return visit (30+ min) | 34 | $6,319 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $5,937 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $4,639 | $70 |
| New patient visit (60+ min) | 22 | $3,585 | $163 |
| Long return visit (40+ min) | 12 | $3,278 | $173 |
| Return visit (30+ min) | 31 | $3,079 | $77 |
| Long return visit (40+ min) | 17 | $3,069 | $123 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,568 | $117 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,166 | $155 |
| Short return visit (20+ min) | 16 | $1,679 | $84 |
| Test for exercise-induced lung stress | 13 | $249 | $19 |
Who their Medicare patients are
237 Original Medicare patients in 2024. Average age 73 · Under 65 17% · 85 and older 15% · Women 54% · Also on Medicaid 35% · Health risk score 2.94. Above the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
Conditions among them: High blood pressure 75% · Heart failure 58% · Chronic kidney disease 53% · Coronary heart disease 52% · Diabetes 45% · COPD 42% · Atrial fibrillation 41% · Depression 27% · Dementia 19% · Cancer 17% · Stroke 14%.
The office billed $588,743, Medicare allowed $104,316 and paid $81,559; for 656 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 237 | 656 | 73 | 2.94 | $588,743 | $81,559 |
| 2023 | 358 | 731 | 73 | 2.65 | $606,068 | $80,171 |
| 2022 | 390 | 833 | 74 | 2.31 | $569,766 | $81,386 |
| 2021 | 315 | 758 | 72 | 2.26 | $360,061 | $65,719 |
| 2020 | 294 | 670 | 70 | 2.69 | $295,587 | $57,846 |
| 2019 | 67 | 161 | 71 | 2.59 | $43,912 | $11,647 |
| 2016 | 123 | 318 | 67 | 3.87 | $62,514 | $28,078 |
| 2015 | 263 | 774 | 68 | 3.67 | $139,861 | $63,881 |
| 2014 | 131 | 333 | 66 | 3.17 | $60,668 | $25,913 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Critical care, first 30-74 minutes | 88 | $37,113 | $189 |
| Return visit (30+ min) | 52 | $6,504 | $88 |
| Long return visit (40+ min) | 24 | $4,887 | $129 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,793 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $4,602 | $110 |
| Critical care, each additional 30 minutes | 18 | $3,138 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $3,136 | $73 |
| New patient visit (60+ min) | 21 | $2,986 | $142 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $2,152 | $120 |
| Test for exercise-induced lung stress | 77 | $1,576 | $19 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $1,536 | $42 |
| Short return visit (20+ min) | 20 | $1,119 | $53 |
| Hospital discharge day management, 30 minutes or less | 12 | $903 | $75 |
| Return visit (30+ min) | 13 | $608 | $47 |
2022: 16 services
| Critical care, first 30-74 minutes | 84 | $37,199 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $5,505 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,524 | $181 |
| Return visit (30+ min) | 29 | $4,375 | $81 |
| Return visit (30+ min) | 26 | $3,637 | $89 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $3,346 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $3,130 | $65 |
| New patient visit (60+ min) | 18 | $2,979 | $165 |
| Long return visit (40+ min) | 13 | $2,373 | $125 |
| Test for exercise-induced lung stress | 102 | $2,294 | $20 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $879 | $73 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $730 | $35 |
| Short return visit (20+ min) | 11 | $594 | $54 |
| Test to measure expiratory airflow and volume | 30 | $212 | $7 |
| Test to examine how well the lungs exchange gases | 24 | $191 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 11 | $104 | $9 |
2021: 15 services
| Critical care, first 30-74 minutes | 31 | $10,747 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $8,114 | $180 |
| Long return visit (40+ min) | 24 | $6,612 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $5,006 | $94 |
| Return visit (30+ min) | 26 | $4,462 | $99 |
| New patient visit (60+ min) | 23 | $4,392 | $191 |
| Return visit (30+ min) | 25 | $3,885 | $97 |
| Long return visit (40+ min) | 15 | $3,746 | $144 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $3,086 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $2,232 | $124 |
| Test for exercise-induced lung stress | 70 | $1,985 | $20 |
| Test to examine how well the lungs exchange gases | 43 | $355 | $8 |
| Test to measure expiratory airflow and volume | 32 | $244 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 24 | $229 | $10 |
| Test to determine lung volumes using sensors | 19 | $212 | $11 |
2020: 14 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $14,517 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $8,298 | $95 |
| Long return visit (40+ min) | 44 | $8,190 | $104 |
| Critical care, first 30-74 minutes | 25 | $6,553 | $199 |
| Long return visit (40+ min) | 25 | $3,905 | $100 |
| New patient visit (60+ min) | 23 | $3,564 | $155 |
| New patient visit (60+ min) | 13 | $1,808 | $139 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 12 | $1,647 | $127 |
| Return visit (30+ min) | 11 | $856 | $78 |
| Test to examine how well the lungs exchange gases | 65 | $522 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 39 | $448 | $11 |
| Test to measure expiratory airflow and volume | 56 | $428 | $8 |
| Test to determine lung volumes using sensors | 24 | $251 | $10 |
| Test for exercise-induced lung stress | 11 | $250 | $21 |
2019: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,493 | $94 |
| Long return visit (40+ min) | 18 | $2,623 | $101 |
| Test to examine how well the lungs exchange gases | 21 | $175 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 12 | $132 | $11 |
| Test to measure expiratory airflow and volume | 17 | $131 | $8 |
2016: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 64 | $10,520 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $10,205 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 63 | $6,001 | $57 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $598 | $31 |
2015: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 176 | $25,148 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 143 | $25,102 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $7,958 | $86 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 40 | $2,500 | $32 |
| Hospital discharge day management, 30 minutes or less | 16 | $974 | $61 |
2014: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 59 | $10,323 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 86 | $8,896 | $59 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 33 | $2,080 | $32 |
| Hospital discharge day management, 30 minutes or less | 15 | $899 | $60 |
Medicaid work
$159 in 2022
Medicaid paid $159 for 30 billed services this clinician did in 2022, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 15 | $95 |
| Diffusing capacity | 15 | $64 |
| 2022 | 30 | 2 | 15 | $159 |
Drugs they prescribed that Part D paid
$2,002,962
Pharmacies billed $2,002,962 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 511) in 2024. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 0%.
278 generic and 233 brand-name prescriptions · $2,002,962 in drug cost · 15 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Opsumit | 58 | $736,277 | $12,694 |
| Uptravi | 18 | $649,155 | $36,064 |
| Tyvaso Dpi | 13 | $292,512 | $22,501 |
| Adempas | 13 | $205,877 | $15,837 |
| Trelegy Ellipta | 34 | $23,582 | $694 |
See all 15 drugs
| Opsumit | 58 | $736,277 | $12,694 |
| Uptravi | 18 | $649,155 | $36,064 |
| Tyvaso Dpi | 13 | $292,512 | $22,501 |
| Adempas | 13 | $205,877 | $15,837 |
| Trelegy Ellipta | 34 | $23,582 | $694 |
| Ambrisentan | 25 | $23,063 | $923 |
| Breo Ellipta | 33 | $12,720 | $385 |
| Eliquis | 18 | $10,419 | $579 |
| Sildenafil Citrate | 61 | $8,772 | $144 |
| Fluticasone-Salmeterol | 12 | $1,201 | $100 |
| Potassium Chloride | 14 | $415 | $30 |
| Montelukast | 31 | $186 | $6 |
| Furosemide | 26 | $172 | $7 |
| Prednisone | 17 | $97 | $6 |
| Omeprazole | 12 | $14 | $1 |
Year by year
| 2024 | 511 | 54 | 0% (0) | 46% | $2,002,962 |
| 2023 | 377 | 71 | 0% (0) | 58% | $1,328,944 |
| 2022 | 422 | 61 | None | 57% | $744,810 |
| 2021 | 369 | 61 | 0% (0) | 40% | $377,045 |
| 2020 | 275 | 52 | 0% (0) | 43% | $53,307 |
| 2019 | 28 | 13 | 0% (0) | None | $4,593 |
| 2017 | 72 | None | 0% (0) | None | $22,842 |
| 2016 | 120 | None | None | None | $21,195 |
| 2015 | 74 | None | None | 15% | $6,392 |
| 2014 | 16 | None | None | None | $117 |
| 2013 | 117 | 28 | None | 15% | $4,093 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Opsumit | 35 | $426,679 | $12,191 |
| Tyvaso Dpi | 15 | $348,987 | $23,266 |
| Trelegy Ellipta | 33 | $31,832 | $965 |
| Anoro Ellipta | 26 | $13,075 | $503 |
| Breo Ellipta | 19 | $8,659 | $456 |
| Sildenafil Citrate | 23 | $6,867 | $299 |
| Eliquis | 12 | $6,572 | $548 |
| Symbicort | 12 | $4,748 | $396 |
| Fluticasone-Salmeterol | 13 | $1,695 | $130 |
| Montelukast | 26 | $406 | $16 |
| Prednisone | 13 | $166 | $13 |
| Omeprazole | 11 | $147 | $13 |
2022: 15 drugs
| Opsumit | 38 | $430,703 | $11,334 |
| Trelegy Ellipta | 41 | $34,598 | $844 |
| Anoro Ellipta | 33 | $15,773 | $478 |
| Eliquis | 12 | $7,360 | $613 |
| Advair Diskus | 15 | $7,071 | $471 |
| Symbicort | 17 | $6,578 | $387 |
| Spiriva Handihaler | 12 | $6,317 | $526 |
| Flovent Hfa | 12 | $5,467 | $456 |
| Wixela Inhub | 22 | $4,547 | $207 |
| Sildenafil Citrate | 36 | $2,591 | $72 |
| Albuterol Sulfate Hfa | 14 | $816 | $58 |
| Alyq | 12 | $322 | $27 |
| Prednisone | 21 | $259 | $12 |
| Montelukast | 24 | $214 | $9 |
| Fluticasone Propionate | 12 | $125 | $10 |
2021: 14 drugs
| Opsumit | 24 | $258,603 | $10,775 |
| Trelegy Ellipta | 17 | $14,557 | $856 |
| Tadalafil | 12 | $14,363 | $1,197 |
| Anoro Ellipta | 19 | $8,679 | $457 |
| Wixela Inhub | 27 | $7,498 | $278 |
| Advair Diskus | 15 | $7,226 | $482 |
| Spiriva | 12 | $5,939 | $495 |
| Symbicort | 11 | $4,954 | $450 |
| Sildenafil Citrate | 14 | $1,841 | $132 |
| Bumetanide | 20 | $943 | $47 |
| Montelukast | 26 | $383 | $15 |
| Prednisone | 29 | $266 | $9 |
| Furosemide | 21 | $151 | $7 |
| Ciprofloxacin | 11 | $74 | $7 |
2020: 7 drugs
| Advair Diskus | 20 | $8,376 | $419 |
| Anoro Ellipta | 18 | $7,813 | $434 |
| Spiriva | 12 | $7,669 | $639 |
| Prednisone | 23 | $240 | $10 |
| Fluticasone Propionate | 19 | $228 | $12 |
| Montelukast | 27 | $185 | $7 |
| Furosemide | 17 | $128 | $8 |
2017: 2 drugs
| Renvela | 11 | $6,623 | $602 |
| Lantus | 11 | $2,801 | $255 |
2016: 7 drugs
| Renvela | 15 | $7,494 | $500 |
| Nifedipine Er | 15 | $260 | $17 |
| Clopidogrel | 15 | $74 | $5 |
| Carvedilol | 14 | $64 | $5 |
| Simvastatin | 11 | $47 | $4 |
| Ranitidine | 15 | $46 | $3 |
| Lisinopril | 14 | $43 | $3 |
2013: 1 drug
| Lisinopril | 12 | $70 | $6 |
Money from drug and device companies
$63 in 2019
A payment is not proof that care is biased.
| EMD Serono | Mavenclad | $63 | 1 payment
|
See the published payment
| EMD Serono | Meals · 2019-10-31 | Mavenclad | $63 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1003127846
- Licence
- CA A141834, PA MD449923California A141834: Current · expires 2028-04-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Internal medicine (207R00000X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2010-06-26
- NPI last updated
- 2024-04-25
- NPI record certified
- 2024-04-25
This is when the NPI record was last certified, not a medical board exam.